NEKTAR THERAPEUTICS·4

Dec 15, 6:05 PM ET

Wilson Mark Andrew 4

4 · NEKTAR THERAPEUTICS · Filed Dec 15, 2023

Insider Transaction Report

Form 4
Period: 2023-12-13
Wilson Mark Andrew
Chief Legal Officer
Transactions
  • Award

    Stock Option

    2023-12-13+325,000325,000 total
    Exercise: $0.50Exp: 2031-12-12Common Stock (325,000 underlying)
Footnotes (1)
  • [F1]This stock option vests over three years from the date of grant, (December 13, 2023) in equal monthly installments based on continued service.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION